Gossamer Bio Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Gossamer Bio Inc (GOSS)
Gossamer Bio Inc stock price live, this page displays NASDAQ GOSS stock exchange data. View the GOSS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Gossamer Bio Inc real time stock price chart below.
What Is the Gossamer Bio Inc Stock Price Today?
The Gossamer Bio Inc stock price today is 1.980.
What Is the Stock Symbol for Gossamer Bio Inc?
The stock symbol for Gossamer Bio Inc is ""GOSS.""
What Stock Exchange Does Gossamer Bio Inc Trade On?
Gossamer Bio Inc is listed and trades on the NASDAQ stock exchange.
Is Gossamer Bio Inc a Good Stock to Buy?
Determining whether Gossamer Bio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GOSS quote. (ISIN: US38341P1021)
What Is the Gossamer Bio Inc Stock Price Today?
The Gossamer Bio Inc stock price today is 1.980.
What Is the Stock Symbol for Gossamer Bio Inc?
The stock symbol for Gossamer Bio Inc is ""GOSS.""
What Stock Exchange Does Gossamer Bio Inc Trade On?
Gossamer Bio Inc is listed and trades on the NASDAQ stock exchange.
Is Gossamer Bio Inc a Good Stock to Buy?
Determining whether Gossamer Bio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GOSS quote. (ISIN: US38341P1021)
NASDAQ
Currency in USD
1.980
+0.140(+7.61%)
Closed·
Pre Market
2.050+0.070(+3.54%)
·
Fair Value
An estimate of a Gossamer Bio's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.840
2.030
52 wk Range
0.662
2.030
GOSS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week High
More Info
Fair Value
An estimate of a Gossamer Bio's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.8402.030
52 wk Range
0.6622.030
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GOSS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Gossamer Bio's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
8.031
Upside
+305.62%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
- Form 8K Gossamer Bio Inc For: 16 June
- Investing.com
- Gossamer Bio Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K Gossamer Bio Inc For: 16 June
- Investing.com
- Gossamer Bio Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Gossamer Bio Inc Company Profile
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Gossamer Bio Inc Earnings Call Summary for Q1/2025
- Q1 2025 revenue of $9.9M exceeded $4.25M forecast; EPS loss of $0.16 beat expected $0.19 loss
- Stock rose 3.96% post-earnings; company maintains 'GOOD' financial health score per InvestingPro
- Strong cash position of $257.9M; focus on pulmonary hypertension treatments
- Top-line results from PROCERA Phase 3 study expected Feb 2026; SERENADA Phase 3 to start Q4 2025
- Analysts forecast 83% revenue decline for FY2025 despite Q1 outperformance
Last Updated: 15/05/2025, 22:48
Read Full TranscriptCompare GOSS to Peers and Sector
Metrics to compare | GOSS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGOSSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.8x | −1.9x | −0.5x | |
PEG Ratio | −0.12 | −0.01 | 0.00 | |
Price/Book | −72.0x | 3.7x | 2.6x | |
Price / LTM Sales | 3.6x | 80.3x | 3.2x | |
Upside (Analyst Target) | 332.6% | 196.2% | 41.2% | |
Fair Value Upside | Unlock | 19.2% | 6.2% | Unlock |
Analyst Ratings
8 Buy
2 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 8.031
(+305.62% Upside)
Earnings
Latest Release
May 15, 2025
EPS / Forecast
-0.16 / -0.19
Revenue / Forecast
9.89M / 4.25M
People Also Watch
FAQ
What Stock Exchange Does Gossamer Bio Trade On?
Gossamer Bio is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Gossamer Bio?
The stock symbol for Gossamer Bio is "GOSS."
What Is the Gossamer Bio Market Cap?
As of today, Gossamer Bio market cap is 450.06M.
What Is Gossamer Bio's Earnings Per Share (TTM)?
The Gossamer Bio EPS (TTM) is -0.23.
When Is the Next Gossamer Bio Earnings Date?
Gossamer Bio will release its next earnings report on 11 Aug 2025.
From a Technical Analysis Perspective, Is GOSS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Gossamer Bio Stock Split?
Gossamer Bio has split 0 times.
How Many Employees Does Gossamer Bio Have?
Gossamer Bio has 145 employees.
What is the current trading status of Gossamer Bio (GOSS)?
As of 29 Jul 2025, Gossamer Bio (GOSS) is trading at a price of 1.98, with a previous close of 1.98. The stock has fluctuated within a day range of 1.84 to 2.03, while its 52-week range spans from 0.66 to 2.03.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.